Tiziana Life Sciences LTD (TLSA) — 6-K Filings

All 6-K filings from Tiziana Life Sciences LTD. Browse 48 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (48)

Tiziana Life Sciences Files 6-K Report — Apr 16, 2026 Risk: low
Tiziana Life Sciences Ltd. filed a Form 6-K on April 16, 2026, reporting as a foreign issuer. The filing includes a press release dated April 16, 2026, and asso
6-K Filing — Apr 14, 2026
Tiziana Life Sciences Files 6-K Report — Apr 1, 2026 Risk: low
Tiziana Life Sciences Ltd. filed a Form 6-K on April 1, 2026, reporting as a foreign issuer. The filing includes a press release dated April 1, 2026, and associ
Tiziana Life Sciences Submits 7th Annual Safety Report to FDA — Dec 29, 2025 Risk: low
On December 29, 2025, Tiziana Life Sciences LTD announced the submission of its seventh annual Development Safety Update Report (DSUR) to the U.S. Food and Drug
6-K Filing — Dec 19, 2025
Tiziana Life Sciences Doses First Patient in Alzheimer's Trial — Dec 17, 2025 Risk: medium
On December 17, 2025, Tiziana Life Sciences LTD announced that the first patient has been dosed with intranasal foralumab in a Phase 2 clinical trial for early
Tiziana Life Sciences Withdraws Public Offering — Dec 15, 2025 Risk: medium
Tiziana Life Sciences Ltd announced on December 15, 2025, the withdrawal of its proposed public offering of common shares. This decision was made due to prevail
6-K Filing — Dec 12, 2025
6-K Filing — Dec 2, 2025
Tiziana Life Sciences' ALS Trial Joins MyMatch Program — Nov 25, 2025 Risk: medium
Tiziana Life Sciences Ltd announced on November 25, 2025, that its Phase 2 clinical trial for intranasal foralumab in ALS patients has been accepted into the AL
Tiziana Life Sciences to Present at Jefferies London Healthcare Conference — Nov 13, 2025 Risk: medium
Tiziana Life Sciences Ltd announced on November 13, 2025, that its senior leadership team, including CEO Ivor Elrifi and COO/CFO Keeren Shah, will present at th
Tiziana Life Sciences to Present at BIO-Europe 2025 — Oct 29, 2025 Risk: low
Tiziana Life Sciences Ltd announced on October 29, 2025, its participation as a presenting company at BIO-Europe 2025. This premier life sciences partnering con
Tiziana Life Sciences Reports Interim Financials & Program Update — Oct 3, 2025 Risk: medium
Tiziana Life Sciences Ltd. filed a Form 6-K on October 3, 2025, reporting its interim financial results for the six months ended June 30, 2025. The filing also
Tiziana Life Sciences Invited to J.P. Morgan Life Science Forum — Sep 30, 2025 Risk: low
Tiziana Life Sciences Ltd. announced on September 30, 2025, that it has been invited to the J.P. Morgan Asset Management, Life Science Innovation Forum (LSIF) 2
Tiziana Life Sciences Advances Anti-IL-6R Antibody TZLS-501 — Sep 25, 2025 Risk: medium
On September 25, 2025, Tiziana Life Sciences LTD announced it is advancing its fully human anti-IL-6 receptor monoclonal antibody, TZLS-501. This move comes ami
Tiziana Life Sciences to Present at ECTRIMS Congress — Sep 24, 2025 Risk: low
Tiziana Life Sciences LTD announced on September 24, 2025, that it will present a scientific poster at the 41st Congress of the European Committee for Treatment
Tiziana Life Sciences Secures DoD Grant for Spinal Cord Injury Therapy — Sep 15, 2025 Risk: medium
On September 15, 2025, Tiziana Life Sciences Ltd announced it received a research grant from the U.S. Department of Defense (DoD) to study intranasal anti-CD3 t
Tiziana Life Sciences CEO Buys Shares — Sep 9, 2025 Risk: medium
On September 9, 2025, Tiziana Life Sciences LTD announced that its CEO, Ivor Elrifi, purchased 193,848 shares of the company's common stock in the open market.
Tiziana Life Sciences Chairman Buys Shares — Sep 5, 2025 Risk: medium
On September 5, 2025, Tiziana Life Sciences Ltd announced that its Executive Chairman and Founder, Gabriele Cerrone, purchased 25,000 common shares at $1.60 per
Tiziana Life Sciences Doses First Patient in MSA Trial — Aug 14, 2025 Risk: medium
Tiziana Life Sciences Ltd. announced on August 14, 2025, that the first participant has been enrolled and dosed in its Phase 2a clinical trial. This trial, taki
Tiziana Life Sciences FDA Approves IND for MSA Trial — Aug 11, 2025 Risk: medium
On August 11, 2025, Tiziana Life Sciences Ltd announced that the U.S. Food & Drug Administration (FDA) has approved the Investigational New Drug (IND) applicati
Tiziana Life Sciences Reports Alzheimer's Treatment Findings — Jul 21, 2025 Risk: medium
On July 21, 2025, Tiziana Life Sciences Ltd announced compelling immunologic findings from treating a moderate Alzheimer's Disease patient with intranasal foral
Tiziana Life Sciences CEO to Present Clinical Findings at Bio Convention — Jun 13, 2025 Risk: medium
Tiziana Life Sciences LTD announced on June 13, 2025, that CEO Ivor Elrifi will present recent clinical findings for the company's lead drug at the Bio Internat
Tiziana Life Sciences Alzheimer's Nasal Spray Featured on NPR — May 23, 2025 Risk: medium
Tiziana Life Sciences Ltd announced on May 23, 2025, advancements in its Alzheimer's disease treatment using its novel nasal spray, Foralumab. This development
Tiziana Life Sciences Study Shows Foralumab Dampens Microglial Activation — May 15, 2025 Risk: medium
Tiziana Life Sciences Ltd announced on May 15, 2025, the publication of a new study in the Journal of 'Clinical Nuclear Medicine'. The study demonstrates that i
Tiziana Life Sciences Founder Buys Shares — May 12, 2025 Risk: medium
On May 12, 2025, Tiziana Life Sciences LTD announced that its Executive Chairman and Founder, Gabriele Cerrone, purchased 15,000 common shares at $1.55 per shar
Tiziana Life Sciences Reports Alzheimer's Treatment Success — May 9, 2025 Risk: medium
On May 9, 2025, Tiziana Life Sciences LTD announced positive results from a PET scan. The scan showed a significant reduction in microglia activation, a marker
Tiziana Life Sciences Starts Dosing at Fourth Site for MS Trial — Apr 23, 2025 Risk: medium
On April 23, 2025, Tiziana Life Sciences LTD announced that dosing has begun at the fourth clinical site for its Phase 2 trial. This trial is evaluating intrana
Tiziana Life Sciences Doses Patients in SPMS Trial at Johns Hopkins — Apr 2, 2025 Risk: medium
Tiziana Life Sciences Ltd. announced on April 2, 2025, that dosing has begun at Johns Hopkins University (JHU) Autoimmunity Center of Excellence for its Phase 2
Tiziana Life Sciences Doses New Patients in MS Trial — Mar 25, 2025 Risk: medium
On March 25, 2025, Tiziana Life Sciences LTD announced the dosing of new patients at Yale MS Center in their multicenter Phase 2 clinical trial. This trial is e
Tiziana Life Sciences CEO to Speak at ROTH Conference — Mar 17, 2025 Risk: low
Tiziana Life Sciences LTD announced on March 17, 2025, that its CEO, Ivor Elrifi, will participate in a fireside chat and host investor meetings at the 37th Ann
Tiziana Life Sciences Regains Nasdaq Listing Compliance — Mar 14, 2025 Risk: low
On March 4, 2025, Tiziana Life Sciences LTD received notification from Nasdaq that it has regained compliance with Nasdaq's minimum bid price listing requiremen
Tiziana Life Sciences Files IND for ALS Phase 2 Trial — Mar 4, 2025 Risk: medium
On March 4, 2025, Tiziana Life Sciences LTD announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration
Tiziana Life Sciences Study Shows Nasal Antibody Reduces Neuroinflammation — Feb 27, 2025 Risk: medium
Tiziana Life Sciences Ltd announced on February 27, 2025, the publication of a study in Nature Neuroscience. The study demonstrated that their anti-CD3 monoclon
Tiziana Life Sciences' Foralumab Shows Promise for Long COVID — Feb 25, 2025 Risk: medium
Tiziana Life Sciences Ltd. announced on February 25, 2025, that its nasal anti-CD3 (foralumab) preclinical study is nearing completion. The company believes for
Tiziana Life Sciences Partners with Renaissance for Nasal Drug Delivery — Feb 21, 2025 Risk: low
On February 21, 2025, Tiziana Life Sciences LTD announced a product development services agreement with Renaissance Lakewood LLC, a Contract Development and Man
Tiziana Life Sciences Doses More MS Patients in Expanded Access Program — Feb 18, 2025 Risk: medium
On February 18, 2025, Tiziana Life Sciences LTD announced the dosing of four additional patients in its Intermediate Size Patient Population Expanded Access (IS
Tiziana Life Sciences Drug Featured on News Channel — Feb 11, 2025 Risk: medium
On February 11, 2025, Tiziana Life Sciences LTD announced that its investigational drug, intranasal foralumab, was featured on a prominent news channel. The seg
Tiziana Life Sciences Faces Nasdaq Delisting Warning — Jan 31, 2025 Risk: medium
On January 29, 2025, Tiziana Life Sciences Ltd received a notice from Nasdaq stating it is not in compliance with the $1.00 Minimum Bid Price Requirement for co
Tiziana Life Sciences Reports SCI Study Results — Jan 24, 2025 Risk: medium
On January 23, 2025, Tiziana Life Sciences LTD announced positive results from studies utilizing a nasal anti-CD3 monoclonal antibody for treating traumatic spi
Tiziana Life Sciences Discovers New MS Biomarkers — Jan 22, 2025 Risk: medium
On January 22, 2025, Tiziana Life Sciences LTD announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple scler
Tiziana Life Sciences: Nasal Antibody Shows Prolonged Benefits — Jan 10, 2025 Risk: medium
On January 10, 2025, Tiziana Life Sciences LTD announced positive findings regarding its nasal anti-CD3 monoclonal antibody. The antibody has shown prolonged be
Tiziana Life Sciences' Foralumab Highlighted in Nature Reviews Neurology — Jan 8, 2025 Risk: medium
On January 8, 2025, Tiziana Life Sciences LTD announced that a review article titled "Immune mechanisms and shared immune targets in neurodegenerative diseases"
Tiziana Life Sciences Doses First Alzheimer's Patient — Dec 17, 2024 Risk: medium
On December 17, 2024, Tiziana Life Sciences LTD announced a significant milestone in its Alzheimer's disease clinical development program. The company successfu
Tiziana Life Sciences Expands Phase 2 SPMS Trial — Dec 4, 2024 Risk: medium
On December 4, 2024, Tiziana Life Sciences LTD announced the expansion of its Phase 2 clinical trial for intranasal foralumab. This trial is evaluating the drug
Tiziana Life Sciences Secures ALS Association Grant — Nov 19, 2024 Risk: medium
Tiziana Life Sciences LTD announced on November 19, 2024, that its grant application to the ALS Association has been approved for funding. This grant is part of
Tiziana Life Sciences Prices $10M Direct Offering — Nov 1, 2024 Risk: medium
On October 30, 2024, Tiziana Life Sciences Ltd. entered into a securities purchase agreement with an institutional investor to sell 5,263,158 common shares. The
Tiziana Life Sciences Reports Positive Anti-Inflammatory Results — Oct 30, 2024 Risk: medium
Tiziana Life Sciences Ltd announced on October 30, 2024, positive results for its anti-CD3 antibody, foralumab, when used in combination with semaglutide. This

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX